Ocugen will host a conference call on November 5, 2025, to discuss Q3 financial results and business updates.
Quiver AI Summary
Ocugen, Inc., a biotechnology company focused on gene therapies for diseases causing blindness, will hold a conference call and live webcast on November 5, 2025, at 8:30 a.m. ET to discuss its financial results for the third quarter of 2025 and provide a business update. A pre-market earnings announcement will be released on the same day. Interested parties can join the call by dialing designated numbers and referencing a conference ID. Ocugen's innovative therapies aim to address complex inherited retinal diseases affecting millions globally, including conditions like retinitis pigmentosa and geographic atrophy. The press release includes a cautionary note regarding forward-looking statements, indicating that actual results may vary from expectations due to various risks and uncertainties. For more details, visit Ocugen's investor website.
Potential Positives
- Ocugen is hosting a conference call and live webcast to discuss its third quarter 2025 financial results, indicating transparency and engagement with investors.
- The announcement of a pre-market earnings release signifies a structured approach to financial reporting, which can build investor confidence.
- Ocugen's focus on gene therapies for blindness diseases highlights its innovative approach in a critical area of unmet medical need, potentially increasing interest from stakeholders in the biotechnology sector.
- The company's modifier gene therapy platform addresses a wide range of complex diseases, which could position Ocugen as a leader in advancements for therapies that impact millions globally.
Potential Negatives
- The press release emphasizes the presence of forward-looking statements, which may raise concerns among investors about the uncertainty of future outcomes for the company.
- The mention of significant risks and uncertainties in relation to the company's predictions may lead to skepticism over the viability of their business model and therapies.
- Ocugen's focus on complex diseases with potential gene network imbalances could indicate challenges in effectively demonstrating the efficacy of their modifier gene therapies compared to traditional therapies, which may affect investor confidence.
FAQ
What date is Ocugen's third quarter 2025 conference call?
Ocugen's third quarter 2025 conference call is scheduled for November 5, 2025.
What time will the conference call take place?
The conference call will begin at 8:30 a.m. ET.
How can I access the live webcast of the conference call?
The live webcast can be accessed on the events section of the Ocugen investor site.
What are the dial-in numbers for the conference call?
The U.S. dial-in number is (800) 715-9871, and the international number is (646) 307-1963.
Will there be a replay of the conference call available?
Yes, a replay and archived webcast will be available for approximately 45 days after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCGN Hedge Fund Activity
We have seen 57 institutional investors add shares of $OCGN stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 13,982,182 shares (-71.4%) from their portfolio in Q2 2025, for an estimated $13,568,309
- MILLENNIUM MANAGEMENT LLC added 4,977,618 shares (+6121.9%) to their portfolio in Q2 2025, for an estimated $4,830,280
- STATE STREET CORP removed 4,593,122 shares (-77.4%) from their portfolio in Q2 2025, for an estimated $4,457,165
- UBS GROUP AG removed 3,713,401 shares (-85.0%) from their portfolio in Q2 2025, for an estimated $3,603,484
- RENAISSANCE TECHNOLOGIES LLC removed 3,459,283 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,356,888
- GEODE CAPITAL MANAGEMENT, LLC removed 3,401,020 shares (-49.4%) from their portfolio in Q2 2025, for an estimated $3,300,349
- VANGUARD GROUP INC removed 1,910,432 shares (-11.5%) from their portfolio in Q2 2025, for an estimated $1,853,883
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCGN Analyst Ratings
Wall Street analysts have issued reports on $OCGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 09/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/24/2025
To track analyst ratings and price targets for $OCGN, check out Quiver Quantitative's $OCGN forecast page.
$OCGN Price Targets
Multiple analysts have issued price targets for $OCGN recently. We have seen 2 analysts offer price targets for $OCGN in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Daniil Gataulin from Chardan Capital set a target price of $7.0 on 09/19/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $7.0 on 06/24/2025
Full Release
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers:
(800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID:
3029428
Webcast:
Available on the
events
section of the Ocugen
investor site
A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site .
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at
www.ocugen.com
and follow us on
X
and
LinkedIn
.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
[email protected]
